Avacta Group, a biotechnology company focused on developing innovative cancer treatments, has successfully raised £10 million through an oversubscribed placing and subscription. The company issued 15.87 million new shares at a price of 63p per share, which represents a 9.4% discount to the closing price prior to the announcement. Strategic Investment in Cancer Innovations The…
Read more
Avacta Secures £10 Million to Propel Cancer Treatment Pipeline Forward



